RT Journal Article
SR Electronic
T1 Integrative Bioinformatics Analysis Identifies Noninvasive miRNA Biomarkers for Lung Cancer
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.12.31.20248963
DO 10.1101/2020.12.31.20248963
A1 Andrew Gao
YR 2021
UL http://medrxiv.org/content/early/2021/01/04/2020.12.31.20248963.abstract
AB Non-small cell lung cancer (NSCLC), a subtype of lung cancer, affects millions of people. While chemotherapy and other treatments have improved, the 5 year survival rate of NSCLC patients is still only 21%. Early diagnosis is essential for increasing survival as treatments have higher effectiveness at earlier stages of NSCLC. Noninvasive blood-based liquid biopsy tests for NSCLC may be useful for diagnosis and prognosis. MicroRNA (miRNA) and messenger RNA present in blood can serve as biomarkers for such tests. The present study identified 13 miRNAs that are underexpressed in the tissue and blood of NSCLC patients using Gene Expression Omnibus data. Following Kaplan Meier analysis, miR-140-3p, miR-29c, and miR-199a were selected as candidate biomarkers and demonstrated statistically significant prognostic power. An ROC analysis of miR-140-3p expression between NSCLC patients and controls had an area under curve value of 0.85. Functional enrichment analysis of the miRNA target genes revealed several overrepresented pathways relevant to cancer. Eight target genes were hub genes of the protein protein interaction network and possessed significant prognostic power. A combination of IL6, SNAI1, and CDK6 achieved a hazard ratio of 1.4 with p < 0.001. These biomarkers are especially valuable because they can be identified in blood and reflect the tumor state. Since all miRNAs were underexpressed in both tissue and blood, detecting expression of a biomarker miRNA in blood provides information on its expression in tissue as well. These miRNAs may be useful biomarkers for NSCLC prognostic and diagnostic tests and should be further studied.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialAs this study only used publicly available data and was computational, no clinical trial ID was necessary.Funding StatementNo funding was received.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:No IRB approval was necessary.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData is freely and publicly available from the Gene Expression Omnibus. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE137140 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE94536 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53882 https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE93300 NSCLCNon-small cell lung cancerLUADLung adenocarcinomaLUSCSquamous cell lung cancermiRNAmicroRNADEMiRNADifferentially expressed microRNA